Immunomic Therapeutics, Inc. ("ITI"), a privately held clinical-stage biotechnology company pioneering nucleic acid-based immunotherapy, today announced that the U.S. Food and Drug Administration (FDA ...

A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.

Biocon recently unveiled three new biosimilar oncology assets to its R&D pipeline —trastuzumab/hyaluronidase (Herceptin ...

The FDA approved adjuvant Keytruda for patients ages 12 and older with stage 2b, 2c or 3 melanoma that has been completely resected. The Food and Drug Administration (FDA) approved adjuvant Keytruda ...

The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with ...

Merck MRK announced that the FDA has approved both the intravenous (“IV”) and the subcutaneous (under the skin or SC) formulation of its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), each in ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph in combination with enfortumab ...

Applications based on Phase 3 KEYNOTE-905 results showing the combination improved event-free survival by 60%, reduced the risk of death by 50% and increased pathologic complete response rates by 48% ...

A meaningful portion of Merck’s MRK revenues comes from its oncology franchise anchored by its blockbuster PD-L1 inhibitor, ...